121 related articles for article (PubMed ID: 9384469)
1. Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.
Zhao XJ; Ishizaki T
Br J Clin Pharmacol; 1997 Nov; 44(5):505-11. PubMed ID: 9384469
[TBL] [Abstract][Full Text] [Related]
2. A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition.
Zhao XJ; Ishizaki T
Eur J Drug Metab Pharmacokinet; 1999; 24(3):272-8. PubMed ID: 10716067
[TBL] [Abstract][Full Text] [Related]
3. The In vitro hepatic metabolism of quinine in mice, rats and dogs: comparison with human liver microsomes.
Zhao XJ; Ishizaki T
J Pharmacol Exp Ther; 1997 Dec; 283(3):1168-76. PubMed ID: 9399990
[TBL] [Abstract][Full Text] [Related]
4. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.
Zhang H; Coville PF; Walker RJ; Miners JO; Birkett DJ; Wanwimolruk S
Br J Clin Pharmacol; 1997 Mar; 43(3):245-52. PubMed ID: 9088578
[TBL] [Abstract][Full Text] [Related]
5. Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes.
Baune B; Furlan V; Taburet AM; Farinotti R
Drug Metab Dispos; 1999 May; 27(5):565-8. PubMed ID: 10220483
[TBL] [Abstract][Full Text] [Related]
6. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
7. Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs.
Bangchang KN; Karbwang J; Back DJ
Biochem Pharmacol; 1992 May; 43(9):1957-61. PubMed ID: 1596283
[TBL] [Abstract][Full Text] [Related]
8. Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs.
Bangchang KN; Karbwang J; Back DJ
Biochem Pharmacol; 1992 Aug; 44(3):587-90. PubMed ID: 1510705
[TBL] [Abstract][Full Text] [Related]
9. Mutual inhibition between quinine and etoposide by human liver microsomes. Evidence for cytochrome P4503A4 involvement in their major metabolic pathways.
Zhao XJ; Kawashiro T; Ishizaki T
Drug Metab Dispos; 1998 Feb; 26(2):188-91. PubMed ID: 9456308
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.
Allqvist A; Miura J; Bertilsson L; Mirghani RA
Eur J Clin Pharmacol; 2007 Feb; 63(2):173-9. PubMed ID: 17200836
[TBL] [Abstract][Full Text] [Related]
11. Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.
Mirghani RA; Yasar U; Zheng T; Cook JM; Gustafsson LL; Tybring G; Ericsson O
Drug Metab Dispos; 2002 Dec; 30(12):1368-71. PubMed ID: 12433805
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
13. Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.
Wang JS; Wen X; Backman JT; Taavitsainen P; Neuvonen PJ; Kivistö KT
Pharmacol Toxicol; 1999 Oct; 85(4):157-61. PubMed ID: 10563513
[TBL] [Abstract][Full Text] [Related]
14. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo.
Mirghani RA; Hellgren U; Westerberg PA; Ericsson O; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1999 Nov; 66(5):454-60. PubMed ID: 10579472
[TBL] [Abstract][Full Text] [Related]
15. Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes.
Harrell AW; Wheeler SM; Pennick M; Clarke SE; Chenery RJ
Drug Metab Dispos; 1993; 21(1):18-23. PubMed ID: 8095215
[TBL] [Abstract][Full Text] [Related]
16. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.
Chiba M; Hensleigh M; Nishime JA; Balani SK; Lin JH
Drug Metab Dispos; 1996 Mar; 24(3):307-14. PubMed ID: 8820421
[TBL] [Abstract][Full Text] [Related]
17. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.
Wang JS; Backman JT; Wen X; Taavitsainen P; Neuvonen PJ; Kivistö KT
Pharmacol Toxicol; 1999 Nov; 85(5):201-5. PubMed ID: 10608481
[TBL] [Abstract][Full Text] [Related]
18. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.
Mirghani RA; Ericsson O; Tybring G; Gustafsson LL; Bertilsson L
Eur J Clin Pharmacol; 2003 May; 59(1):23-8. PubMed ID: 12743670
[TBL] [Abstract][Full Text] [Related]
19. Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
Wanwimolruk S; Paine MF; Pusek SN; Watkins PB
Br J Clin Pharmacol; 2002 Dec; 54(6):643-51. PubMed ID: 12492613
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.
Funck-Brentano C; Becquemont L; Lenevu A; Roux A; Jaillon P; Beaune P
J Pharmacol Exp Ther; 1997 Feb; 280(2):730-8. PubMed ID: 9023285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
